The results of an in vitro trial suggested that Sirt1/FoxO1 may be one of the potential therapeutic targets for LPS‐induced oxidative stress injury in rat insulinoma cells (Mo et al., 2019). The gene discussed is FOXO1; the disease is pancreatic insulinoma.